BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BC Innovations | Jun 27, 2019
Distillery Therapeutics

4-1BBL fusion protein boosts T cell bispecific Abs for gastric cancer and lymphoma

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer; lymphoma Tumor-targeted 4-1BBL fusion proteins could enhance the efficacy of T cell bispecific antibodies to treat gastric cancer and lymphoma. The fusion proteins consist of a trimer of the...
BC Innovations | Apr 10, 2019
Tools & Techniques

Microbiome makes its mark outside the gut

Microbiome makes its mark outside the gut The gut microbiome wasn’t the only population of bacteria under the spotlight at this year’s American Association for Cancer Research (AACR) meeting. A growing focus was on the...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Innovations | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
BC Innovations | Apr 24, 2018
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest CAR T cell therapies targeting CEACAM5 could help treat neuroendocrine prostate cancer. Bioinformatics analysis of 7,555 human cell surface proteins, and transcriptomic and proteomic analyses of eight human...
BC Extra | Apr 23, 2018
Preclinical News

CAR T against cell surface proteins to treat prostate cancer

Researchers at University of California Los Angeles identified cell surface targets to treat prostate adenocarcinoma and neuroendocrine prostate cancer, two distinct major subtypes of advanced prostate cancer, and suggested that CAR T cell therapy against...
Items per page:
1 - 10 of 227